Fibrotic Lung Disease Archives

Respiratory Organizations Tackle the Challenge of Reducing Delays in Diagnosing Complex Lung Diseases

American College of Chest Physicians (CHEST), Chronic Fibrosing Interstitial Lung Diseases (ILD), Fibrosis, Idiopathic Pulmonary Fibrosis (IPF), Initiatives, Lung Disease, Nonprofit, R&D, Respiratory

Three Lakes Foundation and the American College of Chest Physicians (CHEST) recently announced their collaboration on a multiphase educational initiative aiming to reduce the time it takes to diagnose patients with Interstitial Lung Diseases (ILD).

Several Players Begin 2022 with New Partnerships in Place

Business, Cancer, Collaborations, Fibrotic Lung Disease, Partnerships, Psychedelic, R&D, Tumors

BioSpace reviewed a busy January 5th for collaboration announcements in the life sciences world.

FDA Approves Boehringer Ingelheim’s Ofev for Wider Use in Lung Disease

Approvals, Blockbusters, Center for Drug Evaluation and Research (CDER), Chronic Fibrosing Interstitial Lung Diseases (ILD), FDA, FDA/Regulatory, Fibrosis, Fibrotic Lung Disease, Lung Disease, New Indications

The U.S. Food and Drug Administration approved Boehringer Ingelheim’s Ofev (nintedanib) for patients with chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype.